Orphan Diseases and Orphan Drugs

Produk Detail:
  • Author : I. Herbert Scheinberg
  • Publisher : Manchester University Press
  • Pages : 228 pages
  • ISBN : 9780719022968
  • Rating : /5 from reviews
CLICK HERE TO GET THIS BOOK >>>Orphan Diseases and Orphan Drugs

Download or Read online Orphan Diseases and Orphan Drugs full in PDF, ePub and kindle. this book written by I. Herbert Scheinberg and published by Manchester University Press which was released on 01 April 1989 with total page 228 pages. We cannot guarantee that Orphan Diseases and Orphan Drugs book is available in the library, click Get Book button and read full online book in your kindle, tablet, IPAD, PC or mobile whenever and wherever You Like.

Orphan drugs in epilepsy

Orphan drugs in epilepsy
  • Author : M. Nikanorova,P. Genton,S. I. Johannessen,C. Johannessen Landmark
  • Publisher : John Libbey Eurotext
  • Release : 18 September 2013
GET THIS BOOK Orphan drugs in epilepsy

All the necessary information on 6 molecules called “orphan drugs” used in the treatment of some epileptic syndromes. More than half of epilepsies start before the age of 20 years and nearly 25% of them are refractory. Two problems arise: - It is essential to treat them so that brain development continues as normally as possible. - There are few drugs available. This work outlines 6 molecules in detail that are specifically used in epileptic encephalopathies. Every aspect of these molecules is discussed, including

Orphan Drugs

Orphan Drugs
  • Author : Elizabeth Hernberg-Ståhl,Miroslav Reljanović
  • Publisher : Elsevier
  • Release : 15 November 2013
GET THIS BOOK Orphan Drugs

This authoritative and comprehensive book makes the reader familiar with the processes of bringing orphan drugs to the global market. There are between 5,000 and 7,000 rare diseases and the number of patients suffering from them is estimated to be more than 50 million in the US and Europe. Before the orphan drug legislation enacted in the US in 1983, there was a limited interest from industry to develop treatment for very small patient groups. One of the difficulties is, of course, that similar

Rare Diseases and Orphan Drugs

Rare Diseases and Orphan Drugs
  • Author : Jules J. Berman
  • Publisher : Academic Press
  • Release : 02 June 2014
GET THIS BOOK Rare Diseases and Orphan Drugs

Rare Diseases and Orphan Drugs shows that much of what we now know about common diseases has been achieved by studying rare diseases. It proposes that future advances in the prevention, diagnosis, and treatment of common diseases will come as a consequence of our accelerating progress in the field of rare diseases. Understanding the complex steps in the development of common diseases, such as cancer, cardiovascular disease, and metabolic diseases, has proven a difficult problem. Rare diseases, however, are often

Orphan Drugs and Rare Diseases

Orphan Drugs and Rare Diseases
  • Author : David C Pryde,Michael J Palmer
  • Publisher : Royal Society of Chemistry
  • Release : 30 July 2014
GET THIS BOOK Orphan Drugs and Rare Diseases

Orphan drugs are designated drug substances that are intended to treat rare or ‘orphan’ diseases. More than 7000 rare diseases are known that collectively affect some 6-7% of the developed world’s population; however, individually, any single, rare disease may only affect a handful of people making them commercially unattractive for the biopharmaceutical industry to target. Ground breaking legislation, starting with the Orphan Drug Act that was passed in the US in 1983 to provide financial incentives for companies to develop orphan

Searching for Magic Bullets

Searching for Magic Bullets
  • Author : Lisa A Basara,Michael E Montagne
  • Publisher : CRC Press
  • Release : 10 August 1994
GET THIS BOOK Searching for Magic Bullets

Searching for Magic Bullets reveals the quest of consumers, health professionals, and drug developers to find safer and faster methods of bringing new medications to the marketplace. Authors Basara and Montagne explore the current drug development and approval processes, their strengths and weaknesses, and the mechanisms by which patients and organizations evade these processes. Readers learn about the fundamentals of traditional and nontraditional drug discovery and development as they occur in the U.S., as well as the views of

Value Assessment of Orphan Drugs and Treatments for Rare Diseases

Value Assessment of Orphan Drugs and Treatments for Rare Diseases
  • Author : Catherine M. Lockhart
  • Publisher : Unknown
  • Release : 21 June 2021
GET THIS BOOK Value Assessment of Orphan Drugs and Treatments for Rare Diseases

OBJECTIVES: In 1983 the US Orphan Drug Act was passed to facilitate commercialization of drugs to treat rare diseases. The market value for orphan drugs in the US reached $90 billion annually in 2014, with worldwide sales forecast at $176 billion. Payers and policymakers need robust methodology for evaluation of health technology in this growing landscape of expensive treatments for rare diseases. Here I present a systematic review of current practices in value-based evaluation of orphan drugs from a global perspective. I also propose

Proceedings of 4th World Congress on Rare Diseases and Orphan Drugs 2018

Proceedings of 4th World Congress on Rare Diseases and Orphan Drugs 2018
  • Author : ConferenceSeries
  • Publisher : ConferenceSeries
  • Release : 21 June 2021
GET THIS BOOK Proceedings of 4th World Congress on Rare Diseases and Orphan Drugs 2018

June 11-12, 2018 | Dublin, Ireland Key Topics : Neglected Tropical Diseases, Rare Pulmonary Diseases, Rare Diseases in Neurology, Rare Genetic Diseases, Scope of Orphan Drugs, Rare diseases of Endocrine System, Rare diseases of Immune System, Rare Cardiac Diseases, Rare Eye and Ear Diseases, Orphan Drugs Treatment for Rare Diseases, Rare Oral Diseases, Rare Hepatic Diseases, Rare Gastrointestinal Diseases, Rare Bacterial, Viral and Fungal infections, Rare diseases of Genitourinary System, Rare diseases in Nephrology, Rare Skin Diseases, Clinical Research on Orphan Drugs, Rare

Orphan Drugs

Orphan Drugs
  • Author : Daniel Hagn,Oliver Schöffski
  • Publisher : Unknown
  • Release : 21 June 2021
GET THIS BOOK Orphan Drugs

"The promotion and development of medicinal products for the treatment of rare diseases require our particular attention, as health is our most valuable possession," said Ursula Schleicher, former Vice-President of the European Parliament. According to estimates, around 25 million people in Europe are suffering from 5,000 to 8,000 orphan diseases. Many of them are still waiting for medicines that will allow them to at least be able to lead a pain-free life, if not always a normal life. From a purely business-management viewpoint,